Global Information
회사소개 | 문의 | 비교리스트

지카 바이러스 감염증 : 파이프라인 리뷰

Zika Virus Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 410983
페이지 정보 영문 258 Pages 배송안내
가격
US $ 2,000 ₩ 2,543,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,086,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,630,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


지카 바이러스 감염증 : 파이프라인 리뷰 Zika Virus Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 258 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

지카 바이러스 감염증은 주로 숲 모기를 매개로 감염됩니다. 지카 바이러스는 플라비바이러스과에 속합니다. 증상은 열, 피부 발진, 결막염, 근육통과 관절통, 불안감, 두통 등입니다. 위험인자로 열대 지역이나 아열대 지역에 체재하는 것 등이 있습니다. 지카 바이러스는 성교에 의해서도 감염됩니다. 치료는 수액 및 약제로 관절통이나 열 등의 증상을 경감시킵니다.

지카 바이러스 감염증(Zika Virus Infections) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

지카 바이러스 감염증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • Bharat Biotech International Ltd
  • Biken Inc
  • BioCryst Pharmaceuticals Inc
  • Biotron Ltd
  • CaroGen Corp
  • Codagenix Inc
  • Ennaid Therapeutics LLC
  • Etubics Corp
  • GeneOne Life Science, Inc.
  • GeoVax Labs Inc
  • Hawaii Biotech Inc
  • Hemispherx Biopharma Inc
  • HSRx Group
  • Humabs BioMed SA
  • Immunovaccine Inc
  • Kineta Inc
  • Mymetics Corp
  • NewLink Genetics Corp
  • Novavax Inc
  • OXIS International Inc
  • PaxVax Inc
  • Pharos Biologicals LLC
  • Plex Pharmaceuticals Inc
  • Prokarium Ltd
  • Protein Sciences Corp
  • Regeneron Pharmaceuticals Inc
  • Replikins Ltd
  • Sanofi Pasteur SA
  • Sirnaomics Inc
  • Spotlight Innovation Inc
  • Starpharma Holdings Ltd
  • Takeda Pharmaceutical Company Ltd
  • Tamir Biotechnology Inc
  • TGV-Laboratories
  • Themis Bioscience GmbH
  • Valneva SE
  • Vaxart Inc
  • VaxInnate Corp
  • VBI Vaccines Inc
  • Visterra Inc
  • VLP Therapeutics LLC

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.02.09

List of Tables

List of Tables

  • Number of Products under Development for Zika Virus Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Zika Virus Infections - Pipeline by Activirosomes Ltd, 2021
  • Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, 2021
  • Zika Virus Infections - Pipeline by Akshaya Bio Inc, 2021
  • Zika Virus Infections - Pipeline by Altimmune Inc, 2021
  • Zika Virus Infections - Pipeline by Aravive Inc, 2021
  • Zika Virus Infections - Pipeline by Autonomous Therapeutics Inc, 2021
  • Zika Virus Infections - Pipeline by Bharat Biotech Ltd, 2021
  • Zika Virus Infections - Pipeline by Biken Co Ltd, 2021
  • Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, 2021
  • Zika Virus Infections - Pipeline by BioNet-Asia Co Ltd, 2021
  • Zika Virus Infections - Pipeline by Biotron Ltd, 2021
  • Zika Virus Infections - Pipeline by BravoVax Co Ltd, 2021
  • Zika Virus Infections - Pipeline by CanSino Biologics Inc, 2021
  • Zika Virus Infections - Pipeline by Cidara Therapeutics Inc, 2021
  • Zika Virus Infections - Pipeline by Ciloa, 2021
  • Zika Virus Infections - Pipeline by Cocrystal Pharma Inc, 2021
  • Zika Virus Infections - Pipeline by Codagenix Inc, 2021
  • Zika Virus Infections - Pipeline by CycloLab Cyclodextrin Research and Development Laboratory Ltd, 2021
  • Zika Virus Infections - Pipeline by Emergent BioSolutions Inc, 2021
  • Zika Virus Infections - Pipeline by Emergex Vaccines Holding Ltd, 2021
  • Zika Virus Infections - Pipeline by Enesi Pharma Ltd, 2021
  • Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, 2021
  • Zika Virus Infections - Pipeline by Enyo Pharma SA, 2021
  • Zika Virus Infections - Pipeline by Eurocine Vaccines AB, 2021
  • Zika Virus Infections - Pipeline by Excivion Ltd, 2021
  • Zika Virus Infections - Pipeline by Expres2ion Biotechnologies ApS, 2021
  • Zika Virus Infections - Pipeline by GeneOne Life Science Inc, 2021
  • Zika Virus Infections - Pipeline by GeoVax Labs Inc, 2021
  • Zika Virus Infections - Pipeline by Greffex Inc, 2021
  • Zika Virus Infections - Pipeline by Grifols SA, 2021
  • Zika Virus Infections - Pipeline by Hawaii Biotech Inc, 2021
  • Zika Virus Infections - Pipeline by Heat Biologics Inc, 2021
  • Zika Virus Infections - Pipeline by Hercules Pharmaceuticals BV, 2021
  • Zika Virus Infections - Pipeline by IDBiologics Inc, 2021
  • Zika Virus Infections - Pipeline by ImmunityBio Inc, 2021
  • Zika Virus Infections - Pipeline by Imutex Ltd, 2021
  • Zika Virus Infections - Pipeline by IMV Inc, 2021
  • Zika Virus Infections - Pipeline by Indian Immunologicals Ltd, 2021
  • Zika Virus Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
  • Zika Virus Infections - Pipeline by iosBio Pharma Ltd, 2021
  • Zika Virus Infections - Pipeline by Island Pharmaceuticals, 2021
  • Zika Virus Infections - Pipeline by Johnson & Johnson, 2021
  • Zika Virus Infections - Pipeline by Kamada Pharmaceuticals, 2021
  • Zika Virus Infections - Pipeline by KM Biologics Co Ltd, 2021
  • Zika Virus Infections - Pipeline by Macrophage Therapeutics Inc, 2021
  • Zika Virus Infections - Pipeline by Medigen Inc, 2021
  • Zika Virus Infections - Pipeline by Meletios Therapeutics SAS, 2021
  • Zika Virus Infections - Pipeline by Microbiotix Inc, 2021
  • Zika Virus Infections - Pipeline by Moderna Inc, 2021
  • Zika Virus Infections - Pipeline by Moleculin Biotech Inc, 2021
  • Zika Virus Infections - Pipeline by NanoViricides Inc, 2021
  • Zika Virus Infections - Pipeline by Novalex Therapeutics Inc, 2021
  • Zika Virus Infections - Pipeline by Orgenesis Inc, 2021
  • Zika Virus Infections - Pipeline by Ostrich Pharma USA Inc, 2021
  • Zika Virus Infections - Pipeline by Palisades Therapeutics, 2021
  • Zika Virus Infections - Pipeline by Pharos Biologicals LLC, 2021
  • Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, 2021
  • Zika Virus Infections - Pipeline by Precision Virologics Inc, 2021
  • Zika Virus Infections - Pipeline by ProtInhi BV, 2021
  • Zika Virus Infections - Pipeline by Replikins Ltd, 2021
  • Zika Virus Infections - Pipeline by Riboscience LLC, 2021
  • Zika Virus Infections - Pipeline by Sanofi, 2021
  • Zika Virus Infections - Pipeline by Sementis Ltd, 2021
  • Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, 2021
  • Zika Virus Infections - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Zika Virus Infections - Pipeline by TechnoVax Inc, 2021
  • Zika Virus Infections - Pipeline by TenGen Biomedical Co, 2021
  • Zika Virus Infections - Pipeline by Themis Bioscience GmbH, 2021
  • Zika Virus Infections - Pipeline by Theravectys SA, 2021
  • Zika Virus Infections - Pipeline by Tiba Biotech LLC, 2021
  • Zika Virus Infections - Pipeline by Touchlight Genetics Ltd, 2021
  • Zika Virus Infections - Pipeline by Tychan Pte Ltd, 2021
  • Zika Virus Infections - Pipeline by VBI Vaccines Inc, 2021
  • Zika Virus Infections - Pipeline by VenatoRx Pharmaceuticals Inc, 2021
  • Zika Virus Infections - Pipeline by Vir Biotechnology Inc, 2021
  • Zika Virus Infections - Pipeline by Virocovax, 2021
  • Zika Virus Infections - Pipeline by Xenothera SAS, 2021
  • Zika Virus Infections - Dormant Projects, 2021
  • Zika Virus Infections - Dormant Projects, 2021 (Contd..1)
  • Zika Virus Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Zika Virus Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Drugs In Development, 2021, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 47, 23 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 16 and 13 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Zika Virus Infections - Overview
  • Zika Virus Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Zika Virus Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Zika Virus Infections - Companies Involved in Therapeutics Development
  • Zika Virus Infections - Drug Profiles
  • Zika Virus Infections - Dormant Projects
  • Zika Virus Infections - Discontinued Products
  • Zika Virus Infections - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q